Share this Page:
This year’s European Society for Medical Oncology (ESMO) Congress was held from 13-17 September 2024, in Barcelona, Spain. The presentations are available to read on the ESMO website. Some affiliates of the International Kidney Cancer Coalition (IKCC) went to the meeting to keep up to date with the care and treatment of patients with kidney cancer.
Take home messages
In abstract LBA74, the results from the LITESPARK-005 study showed that for patients with advanced kidney cancer who had already been treated with immunotherapy or targeted therapy, belzutifan increased the time to when the cancer started growing again compared to everolimus. Also, more patients responded to treatment with belzutifan compared to everolimus. Belzutifan was relatively well tolerated, and no new side effects were reported.
In abstract LBA73, the TiNivo study showed that treatment with a second line of immunotherapy did not improve patient outcomes and should be discouraged in patients with advanced kidney cancer. Furthermore, the findings suggest that tivozanib alone is effective for patients whose cancer progresses on immunotherapy.
In abstract 1690O, NKT2152 was shown to be effective in heavily pretreated, high-risk patients with advanced kidney cancer. The side effect profile was as expected for a HIF-2α inhibitor. Two dose regimens have been selected and are being looked at in the second part of this study.
In abstract LBA76, the combination of new anti-cancer medications benmelstobart + anlotinib (an immunotherapy plus a targeted therapy) improved survival and response to treatment compared with sunitinib in patients with previously untreated advanced kidney cancer. The combination had manageable side effects. These results support the use of benmelstobart + anlotinib as a new first-line treatment for advanced kidney cancer.
In abstract LBA77, early results from the TACITO study show the role of faecal microbiota transplantation in increasing the effectiveness of immunotherapy-based treatments for metastatic kidney cancer patients for the first time.
In abstract LBA75, the SUNNIFORECAST study shows a survival benefit for patients with non-clear cell kidney cancer treated with the ipilimumab + nivolumab combination compared to standard of care. This is the first randomised trial that compares an immunotherapy combination with standard of care in patients with non-clear cell kidney cancer.
